On (b)(6) 2020, the (b)(6) laboratory technologist was verifying the backup dose of cells (autologous cryopreserved hpc, apheresis) in storage for a patient who will undergo a second transplant as part of their cancer treatment.Their cells were collected on (b)(6) 2014 and have been in storage since this time.Upon visually inspecting the cryo bags while verifying the product cells are present and intact, the (b)(6) laboratory technologist discovered a fracture on one of the cryo bags extending from the base of the bag to the top of the bag just under the access port.The patient has an acceptable cell dose to proceed to transplant with the remaining intact product.Review of deviation reporting does not indicate a trend of integrity failures in association with the affected cryo bag lot and/or any other lot of cryo bag.Fda safety report id # (b)(4).
|